Vancouver, April 09, 2019 (GLOBE NEWSWIRE) -- Precision NanoSystems (PNI), a biotechnology company pioneering innovative solutions for the development of genetic nanomedicines used in oncology, rare disease and infectious disease, announced today the launch of its Clinical Solutions service. PNI is offering this new service as a response to repeated requests from clients progressing their programs towards the clinic for support across all aspects of nanomedicine clinical development. Clinical Solutions offers clients a flexible, customizable suite of products and services designed to accelerate the clinical and commercial development of Gene and Cell Therapies.
Clinical Solutions maximizes the effectiveness of clinical and commercial nanomedicine development by leveraging client capabilities and resources with Precision’s NanoAssemblr technology, nanomedicine development services, and value-added partners. The service’s flexibility enables solutions for both virtual companies and multinational Pharmaceutical organizations developing nanomedicines.
“We are dedicated to enabling the success of our client’s nanomedicine development programs”, said Euan Ramsay, Chief Commercial Officer of Precision. “Clinical Solutions is designed to provide a one-stop-shop for all nanomedicine clinical development needs, such as, sourcing GMP excipients, developing analytical methods, building Quality Management Systems or accessing experienced Contract Manufacturing Organizations.”
To celebrate the formal launch of the Clinical Solutions service, Precision is sponsoring a symposium “The Future of GMP Drug Manufacturing from Small Molecules to Nanomedicines: Opportunities and Challenges” hosted by the University of Strathclyde, Glasgow, Scotland. The symposium will explore the challenges and opportunities for the clinical development and commercial supply of different therapeutic modalities as patient treatment evolves from population-based to precision medicine. The symposium is scheduled for Wednesday, April 10 from 9 AM - 10:30 AM and the session will be recorded and made available as a future webinar series.
About Precision NanoSystems Inc.
Precision NanoSystems Inc. (PNI) proprietary NanoAssemblr Platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues in the body. PNI provides instruments, reagents and services to life sciences researchers, including pharmaceutical companies, and builds strategic collaborations to revolutionize healthcare through nanotechnology. For more information, visit www.precisionnanosystems.com . For more information on Clinical Solutions visit www.precisionnanosystems.com/services/clinical-solutions
Speaker Biographies for “The Future of GMP Drug Manufacturing from Small Molecules to Nanomedicines: Opportunities and Challenges”
Dave Tudor, Ph.D. Managing Director of the Medicines Manufacturing Innovation Centre (MMIC). Dr. Tudor, the initial focus of MMIC is on technology translation for small molecule drug manufacture. With a collaborative innovation culture and state-of the art facilities, the new facility will enable industry, academia, healthcare providers and regulators to work collaboratively to address challenges and maximize technology opportunities within the medicines supply chain.
Gavin Halbert, Ph.D.
Professor Gavin Halbert, Director, Cancer Research UK Formulation Unit, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde. Related research is also conducted in drug targeting and delivery systems for cancer chemotherapy for example the utilisation of synthetic Low-Density Lipoprotein systems, the biopharmaceutical assessment of new oral drugs and formulations and the application of continuous manufacturing systems.
Lloyd Jeffs, Ph.D. Director of Clinical Manufacturing Solutions, Precision NanoSystems, Inc. He brings 20 years of experience in the Biotechnology industry working Lipid-based drug delivery systems and has previously worked for Northern Lipids Inc. and Arbutus Biopharma Corporation. He has expertise in formulation and process development and has played key roles in the Technology Transfer and GMP manufacture of RNA-based Lipid Nanoparticles to support multiple clinical stage product candidates.
Jane Alleva Precision Nanosystems 7788775473 jalleva@precision-nano.com
